FDA Approves Besifloxacin Drops for Treatment of Bacterial Conjunctivitis

June 1, 2009

MedPage Today reported last week that the FDA had approved besifloxacin ophthalmic suspension 0.6% (Besivance) for the treatment of bacterial conjunctivitis. Besifloxacin is made by Bausch & Lomb.

The approval was based on clinical trials showing that patients using the drug had a faster rate of infection resolution than those treated with placebo. Fewer than 3% of patients in the trials reported adverse events, which included redness of the eyes, blurred vision, eye pain, irritation and itching, and headache.

Read the full article.




Jump down to form below to submit your own comments

Comments are closed.